Andrea E. Wahner Hendrickson

Andrea E. Wahner Hendrickson, M.D., is an Associate Professor of Oncology and Assistant Professor of Pharmacology at the Mayo Clinic College of Medicine and Science. She holds primary appointments as a Consultant in the Division of Medical Oncology and serves as Interim Medical Director of the Early Phase Therapeutics Novel Agents Disease Team. Her research focuses on developing novel therapies for ovarian cancer, including PARP inhibitors and pharmacogenomics of platinum-taxane chemotherapy. She leads phase I clinical trials and investigates mechanisms of drug resistance and genomics of chemotherapy-induced neuropathy.

• Education: MD from University of Minnesota Medical School, postgraduate training in Hematology/Oncology at Mayo Clinic.
• Key Roles: Co-Principal Investigator in NRG trials, member of National Comprehensive Cancer Network Ovarian Cancer Guidelines panel.

Her research interests include translational studies on ovarian cancer biology, optimizing therapeutic targets, and improving patient outcomes through personalized medicine. Over 5,000 patients have been studied in her pharmacogenomic work on peripheral neuropathy. She has received NIH-funded grants and awards, including the Paul Calabresi Career Development Award.

• Awards: Mayo Clinic Ovarian SPORE Award, Outstanding Medical Oncology Fellow Award.

Dr. Hendrickson collaborates widely, engaging in international initiatives like the Mayo Clinic/Karolinska Institutet collaboration. Her work bridges clinical trials and laboratory research, aiming to streamline novel agent development from bench to bedside.